Big Pharma leading in access-to-medicine strategies, shows data
European Pharmaceutical Review
NOVEMBER 16, 2022
To ensure people in LMICs have access to new and innovative medicines and vaccines as soon as possible after launch, companies need to have an access plan in place for products in the pipeline from at least Phase II of R&D. Novartis signed the first licence for a non-communicable disease (NCD) product, a leukaemia medicine.
Let's personalize your content